| Document |
Document Title |
|
WO/2007/004705A1 |
A glycolipid derivative represented by the formula (I): (I) wherein R1 represents an aldopyranaose residue, R2 represents a hydrogen atom or a hydroxyl group, A represents -CH2-,-CH(OH)-CH2- or -CH=CHCH2-, Z represents -O- or -CH2-, and ...
|
|
WO/2007/000967A1 |
A remedy for cerebral infarction which contains glycyrrhizin and/or a pharmaceutically acceptable salt thereof as the active ingredient. As the pharmaceutically acceptable salt, use may be appropriately made of glycyrrhizin ammonium salt...
|
|
WO/2006/136429A1 |
The present invention relates to compounds of the formula (I); wherein R1 Js H, CH3 or OCH3; R3 = H, OH, CH3, OCH3, O-glucose or benzoyloxy; R4 = H; R5 = H or OH; R6 = H or OCH3; R7 = H, CH3, OCH3, cinnamoyloxy or (3,4,5-trimethoxy)-benz...
|
|
WO/2006/136933A2 |
A composition for the treatment and/or prevention of attacks by biological agents characterised in that it comprises at least: a modulator means; a by-product of Brassicaceae seeds; water.
|
|
WO/2006/135083A1 |
Disclosed are a pharmaceutical for the prevention or treatment of visceral fat syndrome and a beverage/food for the prevention or amelioration of the disease. A prophylactic or therapeutic agent for visceral fat syndrome comprising luteo...
|
|
WO/2006/135084A1 |
Disclosed are a pharmaceutical for the prevention or treatment of steatohepatitis, particularly non-alcoholic steatohepatitis or fatty liver and a beverage/food for the prevention or amelioration of the disease. A prophylactic or therape...
|
|
WO/2006/134352A1 |
The present invention relates to methods of preparing anthocyanins, and methods of preparing precursors of anthocyanins. The methods utilise a coupling reaction between a sugar and a suitable electrophilic precursor to form Eastern half ...
|
|
WO/2006/133447A1 |
Described are novel crystalline pivaloyl furanoses and methods of crystallizing the pivaloyl furanoses. These compounds are useful as intermediates in the synthesis of compounds such as the deoxyjirimycins and nojirimycins and are partic...
|
|
WO/2006/128738A1 |
The invention relates to a composition for depigmenting the skin comprising a compound of formula (I) : in which: - S represents a monosaccharide or a polysaccharide containing up to 20 sugar units; - the bond S-CH2 being a C-glycoside b...
|
|
WO/2006/129075A1 |
The present invention provides processes for the production of polysaccharides containing the L-iduronate subunit, for example, heparin-type polysaccharides. New intermediate compounds and processes developed during the production of sai...
|
|
WO/2006/123558A1 |
It is intended to enable the synthesis of a saccharide derivative (for example, a polysaccharide, a glycolipid, a sugar amino acid, etc.) designed depending on the purpose at a low cost and a high yield by the phase dissolution/phase sep...
|
|
WO/2006/124012A2 |
The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions an...
|
|
WO/2006/120576A2 |
An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit ...
|
|
WO/2006/122296A1 |
Described herein are novel cerebroside compounds, designated as Turbostatin 1, Turbostatin 2, Turbostatin 3, and Turbostatin 4. These compounds were extracted and isolated from the marine mollusk Turbo stenogyrus, and their structures el...
|
|
WO/2006/120208A1 |
The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1 and R3 are defined according to claim 1. Furthermore this inventions relates to intermediates obtained in these processes.
|
|
WO2006099245A9 |
Methods of treating sirtuin related disorders and compounds useful in treating sirtuin related disorders are described.
|
|
WO/2006/119402A2 |
Compounds of the formula: (I) are described, along with pharmaceutical compositions containing these compounds, and methods of using the compounds to prevent and to treat cancer in mammals, including humans.
|
|
WO/2006/115312A1 |
The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering ...
|
|
WO/2006/111616A1 |
The invention relates to the method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus. The in...
|
|
WO/2006/111783A1 |
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and auto...
|
|
WO/2006/108903A1 |
A novel synthesis process for preparing sulphur/phosphorus (S/P) bidentate ligands from carbohydrates is described. The resulting novel compounds are thioglycoside derivatives with one anomerically positioned sulphur atom, meaning that t...
|
|
WO/2006/107097A1 |
A nasal vaccine capable of inducing an effective immunoreaction in the nasal cavity is provided. Specifically, a nasal vaccine comprising a compound having an action of NKT cell activation, particularly, a compound such as (2S,3S,4R)-1-(...
|
|
WO/2006/104530A1 |
Conjugates that are useful for delivering a therapeutic agent to kidney cells are described. The conjugates include saccharides that target the conjugates to kidney cells. The targeting portion of conjugate preferably employs the bi-ante...
|
|
WO/2006/100091A1 |
The invention relates to compounds of formula A-(B)x-C where A = a reducing di- or tri-saccharide, B = 2 - 4C polyvalent alcohol or the derivatives thereof, C = a branched or unbranched, saturated or unsaturated, fatty alcohol with 8 to ...
|
|
WO/2006/098699A1 |
Glycolipids of branched chain alkyl oligosaccharides according to this patent comprise of a primary alcohol branched in the 2-position and an oligosaccharide, covalently bond to the alcohol in either &agr - or β-linkage (shown in Formul...
|
|
WO/2006/096665A1 |
A method of synthesizing Rl, R2-substituted-4' (ax. or eq.)-OH anthracyclines and their corresponding salts of Formula (1) from daunorubicin or N-Trifluoroacetyl-4- Rl - derivatives of daunorubicin, wherein Rl is defined as H, OH, and 4'...
|
|
WO/2006/096606A1 |
Compounds for the inducing apoptosis in cancer cells are described. The described compounds induce the translocation of protein kinase C-&dgr to the mitochondria and the phosphorylation of mitochondrial phospholipid scramblase 3. The com...
|
|
WO/2006/093202A1 |
A phloroacyphenone glycoside represented by the general formula (1): wherein R1 represents an isopropyl, isobutyl or sec-butyl group.
|
|
WO/2006/093352A1 |
A compound represented by the general formula (1') or a salt thereof: (1') wherein R represents an aldopyranose residue, R2 represents a hydrocarbon group having 2 to 18 carbon atoms which may have a substituent; R3 represents an acyl gr...
|
|
WO2005075453A9 |
A novel linker compound that minimizes any nonspecific hydrophobic interactions and is capable of easily regulating the length to disulfide group subjected to metal bond to thereby enable efficient formation of metal-sulfur bond; a novel...
|
|
WO/2006/088017A1 |
An oligosaccharide having at an end thereof a 4-position halogenated galactose residue represented by the following formula (I); a transferase inhibitor containing the oligosaccharide; a method of inhibiting a sugar chain elongation reac...
|
|
WO/2006/088256A1 |
A process for producing a glycoside compound having a trans configuration selective for the 2-position hydroxy group from (a) a furanose compound or pyranose compound and (b) an alcohol compound, characterized in that use is made of a fu...
|
|
WO/2006/083019A1 |
Disclosed is an amyloid β protein aggregation inhibitor. The inhibitor comprises a compound represented by the chemical structure composed of a monosaccharide or a sugar chain having two or more monosaccharides, wherein a part or all of...
|
|
WO/2006/077851A1 |
Disclosed is a compound having an excellent platelet agglutination inhibitory effect. Specifically disclosed is a quinolone derivative characterized by having an amide group at the 3-position which is substituted with a substituent havin...
|
|
WO/2006/067883A1 |
A novel nonionic surfactant consisting of a cellooligosaccharide derivative wherein the position of introduction of hydrophobic groups is unevenly distributed along the main chain of cellulose; and a process for producing the same. There...
|
|
WO/2006/067173A2 |
The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being com...
|
|
WO/2006/064914A1 |
This invention provides a novel compound having irreversible inhibitory activity against neuraminidase, and a therapeutic agent and a detecting agent for neuraminidase-related diseases. Specifically, there are provided a compound of form...
|
|
WO/2006/066020A2 |
Activated polymeric bicine derivatives such as, formula (A) as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
|
|
WO/2006/066059A1 |
Hydrophobically modified polyol compounds comprising from 5 to 11 hydroxy moieties, wherein at least one hydroxy moiety further comprises an alkoxy moiety, and one of the hydroxy or alkoxy moieties comprises an anionic capping unit; comp...
|
|
WO/2006/066060A1 |
A hydrophilically modified polyol compound comprising from 5 to 11 hydroxy moieties, wherein at least one hydroxy moiety further comprises one or more ethoxy moiety, further comprising an anionic capping unit, a cationic capping unit or ...
|
|
WO/2006/060728A2 |
The present invention concerns methods and compositions involving modified LcrV proteins from Yersinia bacteria. These methods and compositions can be employed to invoke an immune response in a subject against the bacteria, while not sup...
|
|
WO/2006/058597A1 |
The invention relates to the novel compounds of formula (I) wherein T, E, R, R , R , R1, R2 and R2 are defined as in claim 1. The novel compounds are suitable as antidiabetics.
|
|
WO/2006/058669A2 |
The present invention relates to aminotetrahydropteridines and processes for the manufacture thereof. In particular, the present invention relates to a process for the manufacture of aminotetrahydrobiopterine. Said compound is an inhibit...
|
|
WO2005092907B1 |
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and auto...
|
|
WO/2006/057406A1 |
A novel compound causing intraoral pungency, such as acridity, represented by the following structural formula (I).
|
|
WO/2006/056604A1 |
Novel levodopa beta-glycosyl derivatives with improved bioavailability and stability, methods of their preparation and use for the treatment of pathological central and peripheral nervous system dysfunctions, neuromotor conditions and ca...
|
|
WO/2006/055437A2 |
The present invention relates to synthetic methods for producing glycodendrimer reagents from disaccharides having a sulhydryl group
|
|
WO/2006/053972A2 |
The invention relates to silanizing agents comprising a saccharide end group and to the use thereof for the functionalization of solid supports. The invention also relates to solid supports that have been functionalized by said silanizin...
|
|
WO/2006/052886A1 |
The invention relates to metabolites of certain [1,4]diazepino[6,7,1-i~]quinoline derivatives and methods of preparation and use thereof. Specifically, the invention relates to compounds of formula I wherein the various substituents are ...
|
|
WO/2006/052930A1 |
The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2”-O-positions as well as their preparation and use as prophylactic or therapeutics against microbial infection.
|
